NCT02413489 2025-02-04An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaJanssen Research & Development, LLCPhase 2 Terminated36 enrolled 18 charts